News
Cassandra Houser Receives AAI Young Investigator Award at the 22nd Annual Upstate New York Immunology Conference
Wednesday, November 6, 2019
IMV Ph.D. Graduate Student, Cassandra Houser (Paige Lawrence's Lab) received one of ten AAI Young Investigator Awards at the 22nd Annual Upstate New York Immunology Conference. The conference this year took place October 28th at Albany Medical Center. The award is based on the top poster abstracts submitted based on scientific rigor and significance to the field of immunology.
Congrats Cassandra!
University of Rochester Researchers Discuss Vaping-Related Lung Injury on the Today Show
Thursday, October 31, 2019
University of Rochester Environmental Health Sciences Center members Daniel Croft, M.D., M.P.H., and Irfan Rahman, Ph.D., were featured on a Today Show segment about vaping-related lung injury. In the segment, Rahman is shown working in his lab while Croft discussed the symptoms associated with this condition.
Rahman uses cell, mouse, and human studies to investigate how flavoring chemicals used in vaping devices affect lung health. He also analyzes vaping liquid collected from patients and hospitals around the world to better understand its chemical makeup. Croft, a clinician researcher who focuses on inhalation toxicology, helps interpret the clinical relevance of findings from the lab and collaborates on a study to better understand respiratory effects in people who vape.
Medical Student Gordon Wong presents at the annual URMC Medical School poster session
Monday, October 21, 2019
Medical Student Gordon Wong presented a poster at the annual URMC Medical School poster session, describing his summer research project. Gordon studied how protein kinase D regulates airway inflammation and epithelial barrier integrity in mouse models of airway inflammation and viral infections. He made some very exciting discoveries, working with graduate student Janelle Veazey, specifically elucidating how protein kinase D controls the recruitment of neutrophils to the lungs.
How environmental toxins impair immune system over multiple generations
Thursday, October 17, 2019
New research shows that maternal exposure to a common and ubiquitous form of industrial pollution can harm the immune system of offspring and that this injury is passed along to subsequent generations, weakening the body's defenses against infections such as the influenza virus.
The study was led by Paige Lawrence, Ph.D., with the University of Rochester Medical Center's (URMC) Department of Environmental Medicine and appears in the Cell Press journal iScience. The research was conducted in mice, whose immune system function is similar to humans.
"The old adage 'you are what you eat' is a touchstone for many aspects of human health," said Lawrence. "But in terms of the body's ability to fights off infections, this study suggests that, to a certain extent, you may also be what your great-grandmother ate."
While other studies have shown that environmental exposure to pollutants can have effects on the reproductive, respiratory, and nervous system function across multiple generations, the new research shows for the first time that the immune system is impacted as well.
This multigenerational weakening of the immune system could help explain variations that are observed during seasonal and pandemic flu episodes. Annual flu vaccines provide some people more protection than others, and during pandemic flu outbreaks some people get severely ill, while others are able to fight off the infection. While age, virus mutations, and other factors can explain some of this variation, they do not fully account for the diversity of responses to flu infection found in the general population.
"When you are infected or receive a flu vaccine, the immune system ramps up the production of specific kinds of white blood cells in response," said Lawrence. "The larger the response, the larger the army of white blood cells, enhancing the ability of the body to successfully fight off an infection. Having a smaller size army — which we see across multiple generations of mice in this study — means that you're at risk for not fighting the infection as effectively."
In the study, researchers exposed pregnant mice to environmentally relevant levels of a chemical called dioxin, which, like polychlorinated biphenyls (PCBs), is a common by-product of industrial production and waste incineration, and is also found in some consumer products. These chemicals find their way into the food system where they are eventually consumed by humans. Dioxins and PCBs bio-accumulate as they move up the food chain and are found in greater concentrations in animal-based food products. The scientists observed the production and function of cytotoxic T cells — white blood cells that defend the body against foreign pathogens, such as viruses and bacteria, and seek out and destroy cells with mutations that could lead to cancer — was impaired when the mice were infected with influenza A virus.
Rochester Researchers Receive $12 Million Award to Visualize the Immune System in Action
Wednesday, October 16, 2019
NIH grant will help identify new strategies to enhance immune response
Cutting-edge imaging technologies that allow scientists to watch the immune system work in real time are leading to a greater understanding of how we combat infection and disease. With a new $12 million grant, researchers will use this knowledge to explore strategies to better fight infections like the flu and beat back overactive immune responses in disorders like rheumatoid arthritis and lupus.
The five-year project, led by Deborah J. Fowell, Ph.D., Dean's Professor in the department of Microbiology and Immunology at the University of Rochester Medical Center, builds on a $9 million grant that her team received in 2014. Both program project grants were awarded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
"When we take cells out of their natural environment and study them in a dish we're missing out on a lot of biology," said David J. Topham, Ph.D., a study project leader and professor of Microbiology and Immunology at URMC. "Imaging and tracking live cells is an emerging theme in immunology and one that I think is going to move forward meaningful discoveries in the field."
In addition to Fowell and Topham, project leaders include Minsoo Kim, Ph.D.,James F. Miller, Ph.D., and Patrick Oakes, Ph.D. Scientists from Cornell and Loyola University will collaborate with the team, as well.
Environmental Toxins Impair Immune System over Multiple Generations
Wednesday, October 2, 2019
New research shows that maternal exposure to a common and ubiquitous form of industrial pollution can harm the immune system of offspring and that this injury is passed along to subsequent generations, weakening the body's defenses against infections such as the influenza virus.
The study was led by Paige Lawrence, Ph.D., with the University of Rochester Medical Center's (URMC) Department of Environmental Medicine and appears in the Cell Press journal iScience. The research was conducted in mice, whose immune system function is similar to humans.
"The old adage 'you are what you eat' is a touchstone for many aspects of human health," said Lawrence. "But in terms of the body's ability to fights off infections, this study suggests that, to a certain extent, you may also be what your great-grandmother ate."
While other studies have shown that environmental exposure to pollutants can have effects on the reproductive, respiratory, and nervous system function across multiple generations, the new research shows for the first time that the immune system is impacted as well.
This multigenerational weakening of the immune system could help explain variations that are observed during seasonal and pandemic flu episodes. Annual flu vaccines provide some people more protection than others, and during pandemic flu outbreaks some people get severely ill, while others are able to fight off the infection. While age, virus mutations, and other factors can explain some of this variation, they do not fully account for the diversity of responses to flu infection found in the general population.
"When you are infected or receive a flu vaccine, the immune system ramps up production of specific kinds of white blood cells in response," said Lawrence. "The larger the response, the larger the army of white blood cells, enhancing the ability of the body to successfully fight off an infection. Having a smaller size army -- which we see across multiple generations of mice in this study -- means that you're at risk for not fighting the infection as effectively."
In the study, researchers exposed pregnant mice to environmentally relevant levels of a chemical called dioxin, which, like polychlorinated biphenyls (PCBs), is a common by-product of industrial production and waste incineration, and is also found in some consumer products. These chemicals find their way into the food system where they are eventually consumed by humans. Dioxins and PCBs bio-accumulate as they move up the food chain and are found in greater concentrations in animal-based food products.
URMC scientist leading nation with vaping research on effects of flavored e-liquids
Thursday, September 26, 2019
New York Gov. Andrew Cuomo is looking to expand the state's newly implemented ban on flavored e-cigarettes to include menthol.
On Thursday, the Democratic governor directed the state's health commissioner to convene an emergency meeting as soon as possible to take steps to include menthol in the first-in-the-nation ban to ban the sale of flavored e-cigarettes. The ban currently excludes tobacco and menthol flavors.
The announcement comes as one local researcher is leading the nation in studying the effects of flavored e-liquids.
Dr. Irfan Rahman with URMC has been researching e-cigarettes in his lab at the School of Medicine for the better part of a decade. The lab has allowed the scientist to take a closer look at vaping and its effects on the body. A few years ago, Dr. Rahman started looking at the makeup of the flavors.
"We know based on our research that the flavors, it doesn't matter what flavors they are or where they come from, those are chemicals," Rahman said.
Rahman, a professor with URMC's Department of Environmental Medicine, said the vaping chemicals are harmful to the lungs.
"They have chest tightness, breathlessness, vomiting, and they're put on a ventilator, so they can get oxygen," he said.
Dr. Rahman said the dozens of tobacco and menthol flavors are no different than the recently-banned vaping flavors.
"Flavors are not fruit juices; they are chemicals," he said. "All these flavors are harmful compared to the air when we just take the oxygen or breathing the air."
The lab's work has played a vital role in uncovering some of the health effects of vaping.
Since June, URMC has treated 16 patients suffering from lung damage related to vaping. That number is up from 12 earlier this month. THC was the common thread.
"Vaping is not safe at all," said Dr. Rahman. "This will lead to hospitalization, even deaths."
The CDC released an update Thursday, reporting at least 805 cases of vaping related lung injuries across 46 states. State Public Health officials said there are a dozen confirmed deaths.
Noah Barclay, 24, switched to using e-cigs a few years ago to help him quit smoking.
"Even before all of this came out, I knew it wasn't good for me," said Barclay, "I used it to quit smoking cigarettes. I don't want to be addicted to nicotine forever, but it's really hard to quit."
Dr. Rahman believes more research needs to be done on the vaping flavors before the number of related illnesses increases even more.
His research is ongoing as new vaping flavors come on the market. Dr. Rahman tests e-liquids purchased at local vape shops and vendors as far away as Europe.
Training for a Cure: CF Researcher Raises Funds for EE
Friday, August 23, 2019
Emily's Entourage (EE) is incredibly honored to have a group of scientists dedicated to accelerating research and drug development for nonsense mutations of Cystic Fibrosis (CF). In the next year, 90% of the CF population could see the benefits of a life-saving drug on the market (currently pending FDA review and approval), but those in the final 10%, including those with nonsense mutations, will not benefit from these new breakthrough drugs.
And in fact, the commitment of the scientists run so deep that it is not merely limited to their "day job" at the lab advancing critical research. Rather, at times, it permeates many aspects of their lives. There is no better example of that than University of Rochester's John Lueck, PhD, who has decided not only to do research to speed breakthroughs and a cure for the final 10%, but also to raise the funds that will drive the critical research.
Over the last few months, Dr. Lueck has trained to climb The Matterhorn in the Swiss Alps, a mountain he tackled on August 22 that reaches almost 15,000 feet high. As a two-time EE grantee through the Catalyst for a Cure Campaign, he flipped the script and committed to raise funds for EE throughout the entire training process!
Congratulations to Anuj Rattan, Postdoctoral Associate in the Sant Lab!
Thursday, August 22, 2019
Anuj has been selected to receive the 2019 Rochester Vaccine Fellowship in honor of Dr. Porter Anderson. The Rochester Vaccine Fellowship is awarded annually to an outstanding postdoctoral fellow working in the area of vaccine-related research, who is mentored by a faculty member with a primary or secondary appointment in the Department of Microbiology and Immunology. This fund was created by a donation from Dr. Michael Pichichero in honor of Dr. Porter Anderson (Professor Emeritus of Pediatrics in Infectious Diseases), who co-invented the widely administered vaccine for bacterial meningitis.
Dr. Georas named the P.I. of Pulmonary T32 Training Grant
Monday, July 1, 2019
On July 1 2019, Dr. Georas became the P.I. of the NIH/NHLBI sponsored Pulmonary T32 Training Grant, replacing Dr. Patricia Sime. Dr. Michael O'Reilly, Professor of Pediatrics and Environmental Medicine, became co-P.I. The Rochester Pulmonary T32 Training Grant is one of the longest continually-funded training grants in the U.S. dedicated to pulmonary research. Drs. Georas and O'Reilly are excited to continue the tradition of excellence in mentorship and training of the next generation of researchers in lung biology and pulmonary medicine.
EHSC Faculty Attend 2019 Center Directors Meeting in Iowa City
Friday, June 21, 2019
The 2019 EHSC Center Directors Meeting was hosted by the University of Iowa in Iowa City on June 20, 21, 2019. University of Rochester's Environmental Health Sciences Center faculty, Irfan Rahman, PhD, CEC Director Katrina Korfmacher, PhD, IHSFC Co-Director Steve Georas, MD, Center Director Paige Lawrence, PhD, and new Center member Daniel Croft, MD, MPH, as well as Center Administrator Pat Noonan Sullivan attended the meeting.
Each faculty member played a role in the meeting, contributing expertise of their work. Rahman spoke on Human health studies of E-cigarette use at the meeting. Discussants included Dana Haine, MS from UNC and Judith Zelikoff, PhD, from NYU, moderated by Alejandro Comellas, MD. Katrina Korfmacher facilitated sessions on policy engagement by CECs and report back of research results to participants and communities. At a break out session on translational research in environmental health sciences, Georas shared the centers experience with the highly successful IHSFC Translational Mini-Pilot Program. Croft presented a poster on his research showing an association between air pollution exposure and hospital admissions for respiratory viral infections.
The 2020 EHSC Center Directors Meeting will be hosted by Wayne State University in Detroit, Michigan July 22nd- 24th, 2020.
New Multi-Institutional Partnership to Focus on Stroke Rehabilitation
Monday, May 20, 2019
The University of Rochester Medical Center (URMC), Burke Neurological Institute, and Wadsworth Center of the New York State Department of Health (NYSDOH) have been awarded a $5 million grant from the Empire State Development Corporation to speed the development of ground-breaking neurological treatments for those disabled from stroke.
The project is a part of the NeuroCuresNY (NCNY) initiative, a new non-profit formed by the three institutions to accelerate the discovery of novel treatments for chronic neurological impairment and disability. The new state funding will support a two-year pilot study that will be launched in January 2020. This study design will be unique because it will test the efficacy of state-of-the-art robotic-assisted rehabilitation technology combined with drugs to improve the functional recovery of stroke patients.
Neurological conditions such as stroke, traumatic brain injury and spinal cord injury permanently disable more than one million people each year in the U.S., and stroke is the nation's leading cause of disability. Clinical trials for neurological disabilities and impairments are usually passed over because of unclear results, high costs, and challenges in recruiting participants. NCNY will seek to lower the barriers to participation in clinical trials by assisting with travel funding for patients, while providing a supportive and guiding environment for patients and their families.
The new study will conducted at the University of Rochester Neurorestoration Institute, led by Bradford C. Berk, M.D., Ph.D., and the Burke Neurological Institute, led by Rajiv R. Ratan, M.D., Ph.D. The National Center for Adaptive Neurotechnologies at the Wadsworth Center of the NYSDOH, led by Jonathan Wolpaw, M.D., will configure the technology that collects and analyzes the research data.
Denise Hocking Honored with UR Research Award
Thursday, May 16, 2019
Pharmacology & Physiology and BME professor, Denise Hocking has been honored with a UR Research Award for her project, Bacterial Pathogens, Fibronectin Mimicry and Intestinal Permeability.
Research in the Hocking lab focuses on understanding the mechanisms by which the extracellular matrix protein, fibronectin, affects cell and tissue functions that are critical for wound repair. We study both the structural mechanisms and intracellular signaling events that mediate cell and tissue responses to matrix fibronectin. In turn, we are using this information to develop novel technologies for tissue engineering, and therapeutic approaches to promote tissue regeneration in chronic wounds.
Congrats Denise!
UR CTSI Student Continues on the Road to Success
Monday, May 13, 2019
Kristen Bush Marshall received her Ph.D. in Translational Biomedical Science in January 2019 and is currently serving as a postdoctoral associate in the Rochester Center for Health Informatics under the mentorship of Martin Zand, M.D., Ph.D. She has just been matched with her top-ranked choice: a field assignment in Denver for a two-year Epidemic Intelligence Service Fellowship. This position with the local health department and the state pf Colorado Department of Public Health and Environment responds to local and state-wide outbreaks allowing Bush Marshall to use her knowledge of healthcare-associated infections.
The University of Rochester School of Medicine and Dentistry has been Chosen as a World Allergy Organization Center of Excellence
Monday, May 6, 2019
John Looney, MD, Kirsi Jarvinen-Seppo, MD. PhD, Steve Georas, MD, Sandy Khurana, MD, and Lisa Beck, MD have been awarded a WAO Center of Excellence. The WAO provides educational outreach programs, symposia and lectureships in 100 countries around the world. Centers of Excellence are tasked with intensifying and accelerating multi-disciplinary scientific and clinical research, education, and training in allergy, asthma and clinical immunology.
CMSR Faculty Jennifer Anolik Named Associate Chair for Research in the Department of Medicine
Tuesday, April 23, 2019
As part of a restructuring to further develop its core research and academic missions, the Department of Medicine has created two new leadership positions. Stephen Hammes, M.D., Ph.D., has been named vice chair for Research and Academic Affairs, and Jennifer Howitt Anolik, M.D., Ph.D., is the associate chair for Research. Both of these appointments were effective April 1,2019, pending approval by the Office of the Provost.
John Lueck Publishes Study on New RNA Technology in Nature Communications
Thursday, March 28, 2019
There are all sorts of "typos" in our DNA that can lead to disease. One kind of typo -- a premature termination codon or PTC -- is responsible for 10 to 15 percent all genetic diseases, including cystic fibrosis and Duchenne muscular dystrophy. PTCs lead to the production of short and often deleterious proteins.
A recent paper by John Lueck, Ph.D., assistant professor of Pharmacology and Physiology and Neurology, shows how high-throughput screening may be used to fix these typos and lessen disease severity. Published in Nature Communications, the study found that modifying tRNA (a type of RNA molecule that helps convert messenger RNA or mRNA into protein) can help the cell make a full length protein, even with a PTC in the middle of the gene. With this new technology to modify tRNA, the authors were able to use gene therapy to suppress faulty versions of a gene in skeletal muscle, and instead force the cells to produce a full-length protein.
At the moment, most investigational therapies for inherited diseases are focused on small molecules, which to this point have not been successful. "For many of these diseases, including cystic fibrosis and Duchenne muscular dystrophy, there are no therapies and patients rely on palliative care," explains Lueck. "Our engineered tRNA platform puts another iron in the fire for development therapeutics and we're hopeful that the technology can be translated into a viable treatment for patients in the near future."
While these studies are still in the early stages, Lueck was recently awarded a unique pilot grant from Vertex Pharmaceuticals to continue this work. This work was funded by Emily's Entourage and the Cystic Fibrosis Foundation and accomplished with the collaboration of researchers at the Cystic Fibrosis Foundations Therapeutics Lab, the Wistar Institute, University of Iowa, and Integrated DNA Technologies, Inc.
Falsey, Mariani Secure $3.8 M NIH Grant to Reduce Antibiotic Overuse
Thursday, February 21, 2019
Ann R. Falsey, M.D., professor of Infectious Diseases, and Thomas J. Mariani, Ph.D., professor of Pediatrics, received a 5-year, $3.8 million grant from the National Institutes of Health to search for a better way to distinguish bacterial and viral respiratory infections. The goal of the study is to define predictive genes -- using gene expression profiling of blood -- that can be developed into a simple point of care diagnostic that can be used by clinicians to discriminate bacterial and non-bacterial illness. Such a test would allow physicians to optimally manage patients with acute respiratory infections, which are a leading cause of antibiotic overuse and are linked to the rise of antibiotic resistant organisms.
The grant is the result of research done as part of the NIH-funded Respiratory Pathogens Research Center. Falsey and Mariani are the co-principal investigators, and Edward Walsh, M.D.,Angela Branche, M.D. and Derick Peterson, Ph.D. are co-investigators.
Ann Falsey & Thomas Mariani Secure 3.8M NIH Grant to Reduce Antibiotic Overuse
Tuesday, February 19, 2019
Ann R. Falsey, M.D., professor of Infectious Diseases, and Thomas J. Mariani, Ph.D., professor of Pediatrics, received a 5-year, $3.8 million grant from the National Institutes of Health to search for a better way to distinguish bacterial and viral respiratory infections. The goal of the study is to define predictive genes -- using gene expression profiling of blood -- that can be developed into a simple point of care diagnostic that can be used by clinicians to discriminate bacterial and non-bacterial illness. Such a test would allow physicians to optimally manage patients with acute respiratory infections, which are a leading cause of antibiotic overuse and are linked to the rise of antibiotic resistant organisms.
The grant is the result of research done as part of the NIH-funded Respiratory Pathogens Research Center. Falsey and Mariani are the co-principal investigators, and Edward Walsh, M.D., Angela Branche, M.D. and Derick Peterson, Ph.D. are co-investigators.
John Lueck Highlighted in Emily’s Entourage
Friday, January 4, 2019
Emily's Entourage (EE) is delighted to learn that John Lueck, PhD was recently given a Vertex CF Research Innovation Award of $750,000 over three years to further his research on nonsense mutations of Cystic Fibrosis (CF). In 2017, through the "Catalyst for a Cure Campaign," EE funded research done by Dr. Lueck, Chris Ahern, PhD, and Paul McCray, MD that focused on using engineered transfer-RNA molecules to genetically repair the W1282X-CFTR nonsense mutation. We are pleased that Dr. Lueck has been given the opportunity to continue this critical groundwork:
"EE's funding brought me into the field of CF research with the specific focus to develop technology for treatment of W1282X. Through the enriching EE scientific community, we have formed collaborations that have propelled our research into new exciting directions that otherwise would not have been explored. Using our results obtained through EE funding as a foundation, we're working to develop optimal delivery methods of our engineered tRNA platform to target nonsense mutations within the CFTR gene in human airway epithelium."
Congratulations, Dr. Lueck, on this incredible award! We're so grateful for your steadfast commitment to accelerating breakthroughs for nonsense mutations of CF! Thank you for seeing beyond to a better future for everyone with CF!
Emily's Entourage is an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of Cystic Fibrosis, a fatal genetic disease afflicting Emily and many others. Named a Champion of Change for President Obama's Precision Medicine Initiative, Emily's Entourage has awarded over $3.4 million in research grants since 2011 and led worldwide efforts to drive high-impact research and drug development.